Furafylline is a potent and selective inhibitor of human cytochrome P450IA2 with an IC50 of 0.07 μM in kinase experiment. Furafylline is a methylxanthine derivative that is introduced as a long-acting replacement for theophylline in the treatment of asthma. Administration of Furafylline is associated with an elevation in plasma levels of caffeine, due to inhibition of caffeine oxidation, a reaction catalysed by one or more hydrocarbon-inducible isoenzymes of P450. Furafylline has either very little or no effect on human monooxygenase activities catalysed by other isoenzymes of P450, including P4501ID1, P4501IC, P450IIIA.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.